Morning Plenary – Thursday, May 10
There are a few reasons why you might recognize Jeff Stewart’s name and face. During his college years, Jeff appeared nine times on the game show Jeopardy! Having swept the College Championship, he landed in second place during the Tournament of Champions, losing in the finals by a single dollar.
Jeff is also one of the “grandfathers” of risk-adjusted net present value. He was the first to publish rNPV—a term we all use today. It first appeared in the 2001 Nature Biotechnology article titled “Putting a Price on Biotechnology.” Since that seminal publication, rNPV has gone on to become the most commonly used valuation method in our industry today.
Jeff currently holds a senior management position in the Corporate Development practice at Campbell Alliance where he has done work for your companies in valuing assets for licensing and M&A.. Prior to joining Campbell, he served as Vice President of Business Development for Caldera Pharmaceuticals, BD Executive at Los Alamos National Laboratory and Owner/Operator at Clinical Capital Group.
Managing Director, BioPharma Investment Banking
Peter Day is a Managing Director in Biopharma Investment Banking at Leerink Swann, having joined the firm in 2001. Prior to Leerink Swann, Peter was an investment banker at William Blair & Company focusing on mergers and acquisitions. During his career, he has completed over 45 transactions, including raising over $2 billion in equity capital for life science companies and advising on M&A transactions with an aggregate value of nearly $5 billion.
Peter received his M.B.A. from Kellogg Graduate School of Management at Northwestern University and his B.A. from Denison University. Prior to business school, he was a risk management consultant at Aon Risk Services. Peter is also a board member and financial officer of the North Suburban YMCA of Boston and previously was co-founder of the Cabrini-Green (Chicago, IL) Chapter of “Soccer in the Streets”.
Luncheon Keynote – Thursday, May 10
Peter N. Kellogg
Executive Vice President & Chief Financial Officer
Merck & Co., Inc.
Peter Kellogg is the Executive Vice President & CFO of Merck & Co., Inc. with responsibility for Merck’s Global Accounting and Controls, Business Planning, Treasury, Tax, Investor Relations and Business Development areas, as well as for coordination of Merck’s Internal Audit organization. Peter joined Merck in his current role in August 2007.
Prior to Merck, Peter served for seven years as the EVP & Chief Financial Officer of Biogen Idec and the former Biogen, Inc. He oversaw the merger of Biogen, Inc. and the Idec Company in 2003. Previously, Peter was an executive with PepsiCo for 13 years in a range of financial and general management positions. He began his career in consulting with Arthur Andersen & Co. followed by Booz-Allen & Hamilton.
Peter earned his B.S. in Engineering from Princeton University and his M.B.A. from the Wharton School of the University of Pennsylvania. He is a member of the Board of Directors of Metabolix, Inc., a producer of bio-based plastics and chemicals; and serves as a business advisor to Theocorp Holding Co., LLC, a company specializing in dental products.
Afternoon Keynote – Thursday, May 10
Walter Moos joined the nonprofit SRI International (formerly Stanford Research Institute) in 2005 as Vice President of the Biosciences Division, a unique organization of more than 250 people with all of the resources necessary to take projects from idea to IND® and beyond. Applying SRI’s Five Disciplines of Innovation to preclinical and clinical research and development, SRI Biosciences provides basic research, drug discovery, and contract services to clients and partners around the world.
During his career, Dr. Moos has made significant contributions to all stages of pharmaceutical R&D, from early stage research to marketed products. Prior to SRI he was Chairman and Chief Executive Officer of MitoKor (Migenix) and a VP of R&D at Chiron (Novartis) and Warner-Lambert/Parke-Davis (Pfizer). His teams have helped to advance a number of drugs and biologics from research to market. Their work has been supported by multiple foundations, government agencies, pharmaceutical and biotechnology companies, venture capitalists, and other sources of funding.
Dr. Moos has served on more than a dozen boards, for example, the Critical Path Institute, Keystone Symposia, Onyx, and Rigel. He has also served as an advisor to academic, government, and investor groups, including the University of Michigan, the National Academy of Sciences, and Red Abbey Venture Partners. Dr. Moos has edited 5 books, helped to found several scientific journals, and has over 150 publications and patents. He received a Ph.D. in chemistry from the University of California Berkeley and an A.B. from Harvard. Dr. Moos is also an adjunct professor at the University of California San Francisco and James Madison University.
He has been married for more than 30 years to Susan M. Miller, Ph.D., a faculty member at the University of California San Francisco. They live in the Oakland hills and have a daughter, Sarah, who is a graduate student in the College of Environmental Design at the University of California Berkeley.
Dinner Keynote – Thursday, May 10
Marc Bonnefoi, DVM, Ph.D.
Head of the North America R&D Hub and Head of Disposition, Safety and Animal Research Scientific Core Platform
A Doctor in Veterinary Medicine and PhD in pharmacology from the University of Toulouse, France, Dr. Marc Bonnefoi was successively teaching assistant in food hygiene and assistant professor (agrégé) in pharmacy and toxicology at the veterinary school of Toulouse, France, Visiting Scientist at the Chemical Industry Institute of Toxicology, Research Triangle Park, NC, and pharmacologist/toxicologist with increasing level of responsibilities at Rhône-Poulenc Rorer, Aventis, sanofi-aventis, and Sanofi.
At Sanofi, Marc Bonnefoi heads the Scientific Core Platform Disposition, Safety and Animal Research, or DSAR, which regroups the talents of over 1000 associates in China, Europe, Japan and the USA to provide Sanofi therapeutic units with quality solutions and expertise in animal research, preclinical and clinical MPK, and preclinical safety from target identification through registration and life-cycle management for small molecules and biological compounds. Through scientific, technological and process innovations, DSAR aims at continuously improving performance, cost effectiveness and impact on projects to better contribute to the success of its current and future partners.
At Sanofi, Marc Bonnefoi is also Head of the North America R&D Hub, which includes the R&D activities of Genzyme, Merial, Pharma, and Sanofi-Pasteur in the region. The vision of the North America R&D Hub is to provide sustained and unique contributions to the success of global Sanofi R&D by creating a highly innovative and collaborative research environment in the region, and developing productive alliances with external academic and business partners.
Externally, Marc Bonnefoi is member of several professional societies, including the French and US Societies of Toxicology, and has served for many years on the Boards of Trustees of the non-for-profit International Life Sciences Institute (ILSI) and Health and Environmental Sciences Institute (HESI). A global branch ILSI, HESI has for mission to stimulate and support scientific research and educational programs that contribute to the identification and resolution of health and environmental issues of concern to the public, scientific community, government agencies, and industry. Marc Bonnefoi is currently the immediate past President of HESI.
International Panel – Focus on Japan
Minako Inenaga, Director- Business Development, Daiichi Sankyo, Inc.
More than 20 years of industry experience in Research, Marketing and Business Development/Planning. The first female expat delegated to a subsidiary in the US (1998), recruited to local position (2000). Global Business Development of Daiichi Sankyo Inc. since the merger of two companies, based in Parsippany, NJ.
Joined Daiichi in 1989 as organic chemist. Moved to International Marketing in 1994. Moved to Daiichi US in 1998 as the first female expat in the pharmaceutical industry in Japan. Recruited to Daiichi US for Business Development/Planning as local employee in 2000. After the merger of Daiichi and Sankyo in 2006, Global Business Development of Daiichi Sankyo Inc. based in Parsippany, NJ.
Frank Borriello, MD, Ph.D., Director, Corporate Development, Millennium: The Takeda Oncology Company
Over 13 years experience in the pharmaceutical and biotechnology industry, in diverse roles spanning oncology clinical development and experimental medicine at Wyeth, financial investment with BB Biotech, consulting and global business development. Most recently at Millennium: The Takeda Oncology Company, he led the BD teams that executed on the Adcetris in-license from Seattle Genetics and the acquisition of Intellikine. Prior to joining the industry he obtained advanced degrees at the Albert Einstein College of Medicine, trained as a clinical pathologist at Harvard’s Brigham and Women’s Hospital, conducted a post-doc in T-cell costimulation and was appointed to an independent research staff position in the Department of Medicine. As a core member of the Millennium Corporate Development Group he is responsible for all oncology related assets and has extensive due diligence experience with protein-based agents as well as conventional small molecules across therapeutic areas including oncology and inflammation, as well as applicable technology platforms.
James Foley, Ph.D., Aqua Partners LLC
Jim’s career in the pharmaceutical industry began in 1977 at the Squibb Institute of Medical Research (E. R. Squibb and Sons). In 1989, he joined the Department of Licensing and Business Analysis at Squibb and relocated to Tokyo to further establish the company’s worldwide pharmaceutical licensing activities in Japan and relationships with Japanese R&D-based pharmaceutical companies. Jim joined SmithKline Beecham’s Worldwide Business Development Team in 1991 as Vice President and Director, Business Development- Japan/Asia, and remained based in Tokyo, representing the company’s worldwide licensing interests in Japan, Asia, and Australia/New Zealand. He returned to the United States in 1995, where he continued his responsibilities based in Philadelphia. In 2002, Jim re-joined Bristol-Myers Squibb as Vice President, Business Development- Japan/International, focused on the identification of strategic R&D collaboration and product licensing opportunities from the Japan, Asia and Australia/New Zealand region. From April 2006 to February 2008, Jim was President and CEO of SMART Biosciences, an early-stage discovery biotechnology company focused on neurodegenerative diseases, particularly Alzheimer’s disease. Jim joined Aqua Partners, a corporate and business development advisory firm focused on strategy development, licensing, M&A and finance for biotechnology and mid-tier pharma companies worldwide, with a special expertise in cross-border relationships and deal making.
Jim serves or has served on the Board of Trustees of St. Peter’s School, Philadelphia, the Boards of Directors of SFJ Pharmaceuticals, ), Traxion (Baltimore), Sosei and Company (Tokyo), the Japan-America Society of Greater Philadelphia and New York Pharma Forum, and the Advisory Boards of the Haub School of Business (St. Joseph’s University, Philadelphia), the Marshall School of Business Global BioBusiness Initiative (University of Southern California, Los Angeles), and Sc Capital I (University City Science Center, Philadelphia). Jim co-chairs the US-Japan Health Sciences Dialogue, an annual meeting held in Philadelphia addressing healthcare issues/solutions in the U.S. and Japan. A member of the Licensing Executives Society (LES), Jim was honored by the organization with the Frank Barnes Mentorship Award. He was designated a Certified Licensing Professional (CLP™) by LES in 2008. Jim holds a Ph.D. in Physiology from Thomas Jefferson University College of Graduate Studies. He received a B.A. in Biology and Chemistry from Rutgers University. He was a NIH Post-Doctoral Fellow from 1975 to 1977 in the Department of Pharmacology, Tulane University School of Medicine.
June Nguyen, Senior Director of Business Development, Eisai
June Nguyen serves as Senior Director, Business Development at Eisai Inc. where she leads business development activities for the Americas Region. Her responsibilities range from identifying and assessing pre-clinical, clinical and commercial opportunities to valuing and analyzing potential licensing and acquisition transactions and negotiating deals. Ms. Nguyen works extensively with multidisciplinary teams, both inside and outside of Eisai, to establish and maintain relationships with potential partners, decision makers and industry leaders.
Ms. Nguyen has been with Eisai since 2005, and has held positions of increasing responsibility in both Business Development and Corporate Strategy. She has had a significant impact on Eisai’s growth, providing leadership for Eisai’s acquisitions of Morphotek, MGI Pharma, and the early stage establishment of H3 Biomedicine. In her most recent role as head of Corporate Strategy, Ms. Nguyen managed the company’s STEP (Social, Technological Environmental and Political) analysis and ongoing environmental monitoring to measure the potential impact to Eisai’s business of changes occurring throughout the US healthcare system.
Prior to joining Eisai, Ms. Nguyen worked as an Equity Research Analyst for Wells Fargo Securities covering Biotechnology. Earlier in her career, she worked in international mergers and acquisitions for a boutique investment bank. Ms. Nguyen holds an M.B.A. in Finance from NYU’s Stern School of Business and a B.S. in Biochemistry and Cell Biology and a B.A. in European History from the University of California, San Diego.
University Panel: Unlocking the Potential of Technology Transfer
Mahmoud Mahmoudian, PhD, FRS, Managing Director, Pharma Partnering, Alborz BioVentures
Dr. Mahmoudian is a Global Bio-Pharmaceutical Executive with a diverse career in big pharma (AZ, GSK, and Merck) and entrepreneurial biotech settings, including emerging markets. He has extensive hands-on experience leading multi-national teams in R&D (discovery, preclinical, and phase I-III), operations, tech transfer, GMP biomanufacturing, and licensure. Dr. Mahmoudian advances corporate development and research strategies by identifying external assets that complement an internal pipeline. He has led cross-functional scientific due diligence teams to evaluate, recommend, and negotiate external innovations in products, platforms, or startups as acquisition targets in multi-million dollar deals across multiple therapies (Oncology, Autoimmune, Cardiovascular, Diabetes, Infectious Diseases, and Neurosciences).
Dr. Mahmoudian’s career spans 20 years in the biotechnology, pharmaceutical, and chemical sectors. He joined Merck in 2007 with responsibility for External Partnerships in vaccines, biologics and biosimilars (Merck BioVenture) on a global basis. Prior to that, he was at Dow as the Global Head of Biotechnology with responsibility for all strategic alliances and research in five sites (US, UK, France, China Japan) generating $600M sales. Dr. Mahmoudian recruited to Eastman earlier in his career as the Worldwide Head of Biotechnology responsible for R&D, partnering, managing growth and development of its BioProducts portfolio. He launched his career with GlaxoSmithKline, where he held a variety of research, technology, and management roles of increasing responsibility in drug discovery, preclinical development and BioPharm R&D.
Vivian Berlin, Director of Business Development, Life Sciences, Harvard University
Vivian joined the Office of Technology Development, Harvard University in 2008. Prior to joining Harvard, Vivian held positions in research management and business development at Vertex Pharmaceuticals, Mitotix and GPC Biotech. She has led multiple R&D programs, advanced programs from discovery to late pre-clinical development, and helped to establish proprietary positions in several therapeutic areas. Vivian holds a BS from Cornell University, MS from the Harvard School of Public Health, a PhD from Stanford University, and was a postdoctoral fellow at the Whitehead Institute for Biomedical Research.
Abram Goldfinger, Executive Director, Industrial Liaison/Technology Transfer, New York University
Mr. Goldfinger is the Executive Director of the Office of Industrial Liaison at New York University, which is responsible for the commercialization of university technologies, and fostering collaborations with industry. He has been involved in academic technology transfer for over 20 years, and has negotiated hundreds of license agreements with industry and participated in the formation of over 90 start-up companies based on university technology. Prior to joining NYU, he was the Director of the Office of Technology Transfer at Thomas Jefferson University, an academic medical center in Philadelphia.
He has been involved in research and development in both industry and academia, including work at the MIT Artificial Intelligence Laboratory, Raytheon Company’s Advanced Systems Laboratory, and several start-up companies. He has also provided consulting to large and small companies and venture capital firms, regarding market analysis, technology assessment, and business plan development.
Mr. Goldfinger received a B.S. in electrical engineering from MIT and an MBA from the Wharton School. He has also passed the Patent Bar Exam and is registered to practice before the U.S. Patent and Trademark Office.
Keith Marmer, Director of the Office of Technology Development, Penn State College of Medicine
Dr. Keith Marmer serves as the Associate Dean for Research Innovation and Director of the Office of Technology Development at Penn State College of Medicine. Dr. Marmer leads efforts for the identification and development of innovative technologies at Penn State Hershey and is focused on the commercialization of Penn State Hershey’s biomedical research platforms. Dr. Marmer brings both academic and entrepreneurial expertise to this role.
Prior to joining Penn State, Dr. Marmer served as Vice President for Technology Transfer and Business Development at the University of the Sciences in Philadelphia where he successfully led a number of entrepreneurial efforts, including the management of the intellectual property portfolio, industry relationship management & sponsored programs and the strategic acquisition of a company. As an entrepreneur, Dr. Marmer was founder and CEO of PhysioMetrics, a national healthcare technology and services firm that performs specialized functional evaluations. Under his leadership, PhysioMetrics successfully raised multiple rounds of investment funding, was awarded People’s Choice for Outstanding Company at the New Jersey Technology Council Venture Capital Conference and received three patents. Dr. Marmer has successfully launched a total of four companies. In addition, he has mentored and consulted to a number of other entrepreneurial ventures as well as taught entrepreneurship to both undergraduate and graduate students.
Dr. Marmer received his MBA as well as his Masters and Doctorate in Physical Therapy from University of the Sciences.
Susan Rohrer, Senior Director, Licensing and External Research, Merck & Co., Inc.
Susan Rohrer has over 20 years of experience in the pharmaceutical industry. Before joining Merck’s Licensing organization in 2004 she served as Senior Director of Biology / Drug Discovery in the Merck Research Laboratories where she studied the mechanism of action of ivermectin, the role of somatostatin receptors in diabetes and selective estrogen receptor modulators for hormone replacement therapy. Within the Licensing and External Research department at Merck, Susan chaired the Neuroscience Review and Licensing Committee. Her recent major licensing deals include Neuromed (NMED-160), Gladstone Institute of Neurological Disease (ApoE mechanisms in neurodegenerative diseases), Addex mGluR5 (schizophrenia), Addex mGluR4 (Parkinson’s disease) and Lycera (RORgt for autoimmune diseases). Susan’s current role within Merck’s External Scientific Affairs Department is Licensing Scout for the Mid-Atlantic and Midwest US. She is a graduate of the University of Michigan (BS) and the University of Notre Dame (PhD).
Ofra Weinberger, Director Columbia Technology Ventures, Columbia University
Dr. Weinberger received a PhD in the field of immunology from Harvard University, where she was a National Science Foundation Scholar in the laboratory of Nobel Laureate Baruj Benacerraf and subsequently continued her postdoctoral training at Harvard in the Department of Genetics. Dr Weinberger then joined the faculty at Columbia University where her research focused on the molecular mechanisms underlying HIV pathogenesis. In light of her interest in facilitating the development and application of insights derived from basic science to the clinical arena, she became involved in technology transfer at the University, and joined Columbia Technology Ventures in 1995. Dr. Weinberger has been Director, Columbia Technology Ventures since 2000. In her capacity as the Health Sciences director, Dr. Weinberger has negotiated and closed multimillion dollar licensing and technology transfer deals, has negotiated multiple substantial research collaboration agreements with industry, foundations, and with other academic institutions, and has negotiated and overseen the spin-out of startup companies from the university.
Columbia Technology Ventures (CTV) is responsible for the development and commercialization of discoveries made during the course of academic research, and for the management of the intellectual property assets of Columbia University. CTV, operational since 1982, has returned over $1.75 billion in revenue to Columbia and is currently managing more than 600 patented technologies, approximately 250 license agreements, and has spun out 70 new companies around technologies discovered in University laboratories. It is the most successful program of its kind in the United States. Roughly 80% of the commercial activity at Columbia relates to the health sciences.
Luncheon Keynote – Friday, May 11
Associate Vice President for Economic Development
Rutgers, the State University of New Jersey
Margaret is Associate Vice President for Economic Development at Rutgers University. She is responsible for the development and implementation of new economic growth initiatives. Her most recent effort is establishing the Innovation Park@Rutgers, a research park that will be located on the Livingston Campus of Rutgers New Brunswick. The Rutgers Discovery Informatics Institute, a core program of the Park, was launched in March 2012. The Institute is an advanced computational center which will broaden access to the state-of-the-art computing technology for academia and industry. Margaret is an Economist with expertise in economic development strategies, energy economics, and industrial organization. She holds a PhD in Planning and Public Policy from Rutgers University.
Manager, Policy & Research
Biotechnology Industry Organization
Charles Crain is the Manager of Policy & Research at the Biotechnology Industry Organization (BIO). As a member of the policy team for BIO’s Emerging Companies Section, his portfolio includes financial services, securities, accounting, and tax issues that affect BIO’s member companies. His particular areas of focus include the JOBS Act, signed into law by President Obama in April 2012; the Therapeutic Discovery Project tax credit; the FASB/IASB convergence project; and other SEC and PCAOB pronouncements important to the biotech industry. Prior to joining BIO, Charles worked on Capitol Hill for Congressman Paul Hodes and Senator Debbie Stabenow. Charles holds a Bachelor’s degree in political science from Mercer University and a Master’s in legislative affairs from The George Washington University.